JP6668340B2 - 新規ｃｈｏ組込み部位およびその使用 - Google Patents

新規ｃｈｏ組込み部位およびその使用 Download PDF

Info

Publication number
JP6668340B2
JP6668340B2 JP2017519646A JP2017519646A JP6668340B2 JP 6668340 B2 JP6668340 B2 JP 6668340B2 JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017519646 A JP2017519646 A JP 2017519646A JP 6668340 B2 JP6668340 B2 JP 6668340B2
Authority
JP
Japan
Prior art keywords
site
exogenous
seq
goi
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535258A5 (enExample
JP2017535258A (ja
Inventor
イン シェン，
イン シェン，
ダリャ ブラコフ，
ダリャ ブラコフ，
ガン チェン，
ガン チェン，
ジェイムズ ピー． ファンデル，
ジェイムズ ピー． ファンデル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6668340(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017535258A publication Critical patent/JP2017535258A/ja
Publication of JP2017535258A5 publication Critical patent/JP2017535258A5/ja
Application granted granted Critical
Publication of JP6668340B2 publication Critical patent/JP6668340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2017519646A 2014-10-23 2015-10-21 新規ｃｈｏ組込み部位およびその使用 Active JP6668340B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
US62/067,774 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (3)

Publication Number Publication Date
JP2017535258A JP2017535258A (ja) 2017-11-30
JP2017535258A5 JP2017535258A5 (enExample) 2018-11-22
JP6668340B2 true JP6668340B2 (ja) 2020-03-18

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519646A Active JP6668340B2 (ja) 2014-10-23 2015-10-21 新規ｃｈｏ組込み部位およびその使用

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434A (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI780847B (enExample)
WO (1) WO2016064999A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12344859B2 (en) 2019-04-02 2025-07-01 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY184103A (en) 2014-10-23 2021-03-18 Regeneron Pharma Novel cho integration sites and uses thereof
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR102906454B1 (ko) * 2016-04-20 2026-01-02 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP4130280A3 (en) * 2016-12-20 2023-04-19 Development Center for Biotechnology Targeted integration sites in chinese hamster ovary cell genome
US20210309988A1 (en) * 2017-02-07 2021-10-07 Sigma-Aldrich Co. Llc Stable targeted integration
KR102719587B1 (ko) * 2017-02-17 2024-10-17 론자 리미티드 아데노-관련 바이러스 생산을 위한 포유동물 세포
WO2018175153A1 (en) * 2017-03-19 2018-09-27 Applied Stemcell, Inc. Novel integration sites and uses thereof
AU2018315428B2 (en) * 2017-08-11 2024-11-14 Boehringer Ingelheim International Gmbh Integration sites in CHO cells
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
US20200318106A1 (en) * 2017-12-22 2020-10-08 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
WO2019126634A2 (en) * 2017-12-22 2019-06-27 Genentech, Inc. Targeted integration of nucleic acids
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
SG11202106523SA (en) * 2018-12-21 2021-07-29 Genentech Inc Targeted integration of nucleic acids
CA3141233A1 (en) 2019-06-26 2020-12-30 Shahram Misaghi Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
WO2021247672A1 (en) * 2020-06-02 2021-12-09 Catalent Pharma Solutions, Llc Nucleic acid constructs for protein manufacture
CN116096907A (zh) * 2020-06-24 2023-05-09 基因泰克公司 核酸的靶向整合
AR123777A1 (es) 2020-10-15 2023-01-11 Hoffmann La Roche Constructos de ácido nucleico para transcripción de arn va
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
US12234472B2 (en) 2021-10-18 2025-02-25 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP4419691A1 (en) 2021-10-18 2024-08-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
JP2024539076A (ja) 2021-10-18 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 安定した組み込み部位を産生するために組み込まれたＣａｓ９遺伝子を含む哺乳動物細胞、並びに安定した組み込み部位及び他の部位を含む哺乳動物細胞
JP2025503925A (ja) * 2022-01-28 2025-02-06 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 異種移植のための遺伝子改変
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240167984A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and determining protein structures and stability in fluids, including biological fluids
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
WO2025054526A1 (en) 2023-09-07 2025-03-13 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ATE539161T1 (de) 1998-07-21 2012-01-15 Millipore Corp Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU2002254529A1 (en) 2001-04-04 2002-10-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CN102625655B (zh) * 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 使用锌指核酸酶在大鼠中进行基因组编辑
SG10201914098YA (en) 2011-04-05 2020-02-27 Scripps Research Inst Chromosomal landing pads and related uses
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
EP2714936B1 (en) * 2011-06-01 2018-12-12 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
JP6188703B2 (ja) * 2011-10-27 2017-08-30 サンガモ セラピューティクス， インコーポレイテッド Ｈｐｒｔ遺伝子座を修飾するための方法および組成物
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
MY184103A (en) 2014-10-23 2021-03-18 Regeneron Pharma Novel cho integration sites and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12344859B2 (en) 2019-04-02 2025-07-01 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene

Also Published As

Publication number Publication date
US20180030480A1 (en) 2018-02-01
EP3209785A1 (en) 2017-08-30
CA2965495C (en) 2022-05-24
US20240018553A1 (en) 2024-01-18
TWI747808B (zh) 2021-12-01
EA037255B1 (ru) 2021-02-26
AU2015335921B2 (en) 2020-06-25
CN107109434A (zh) 2017-08-29
MX2017005306A (es) 2018-01-09
KR102243243B1 (ko) 2021-04-22
US20210171984A1 (en) 2021-06-10
WO2016064999A1 (en) 2016-04-28
IL251674B (en) 2020-10-29
US20160115502A1 (en) 2016-04-28
IL251674A0 (en) 2017-06-29
CA2965495A1 (en) 2016-04-28
JP2017535258A (ja) 2017-11-30
MY184103A (en) 2021-03-18
AR102420A1 (es) 2017-03-01
SG11201703149RA (en) 2018-02-27
US11788102B2 (en) 2023-10-17
BR112017008022A2 (pt) 2018-02-20
KR20170096999A (ko) 2017-08-25
US20200002732A1 (en) 2020-01-02
EA201790698A1 (ru) 2018-01-31
AU2015335921A1 (en) 2017-05-04
EP3209785B1 (en) 2019-07-31
US11268109B2 (en) 2022-03-08
TWI780847B (zh) 2022-10-11
US9816110B2 (en) 2017-11-14
TW201629229A (zh) 2016-08-16
TW202144576A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
JP6668340B2 (ja) 新規ｃｈｏ組込み部位およびその使用
JP2021512617A (ja) ＣｏｒｙｎｅｂａｃｔｅｒｉｕｍにおいてＣＲＩＳＰＲを使用するゲノム編集
CN106520829B (zh) 一种终止双等位基因转录的方法
EP1815001B1 (en) Gene trap cassettes for random and targeted conditional gene inactivation
E Tolmachov Building mosaics of therapeutic plasmid gene vectors
CN117660352A (zh) Nfat5基因定点整合宿主细胞
EP4612306A2 (en) A screening method
JP5999602B2 (ja) 遺伝子ターゲティングベクター、その作製方法及び利用方法
WO2021224506A1 (en) Crispr-cas homology directed repair enhancer
HK1235432B (en) Novel cho integration sites and uses thereof
HK1235432A1 (en) Novel cho integration sites and uses thereof
Schnütgen et al. High throughput gene trapping and postinsertional modifications of gene trap alleles
JP2025522793A (ja) 編集可能な細胞株
CN121079425A (zh) 可再编辑的模板、细胞、组合物和制备方法
WO2026017676A1 (en) A novel genomic safe harbor site in the actb locus
Zhang CRISPR/Cas9-based Genome Editing Approaches for Gene Disruption and Application in Disease Therapy
CN117597439A (zh) Ciita靶向锌指核酸酶
HK40119722A (zh) 可编辑细胞系

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200226

R150 Certificate of patent or registration of utility model

Ref document number: 6668340

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250